证券记录 · 已归档季度
CYTK
Cytokinetics, Incorporated · Healthcare · Biotechnology
11被追踪持有人
—Δ持有人
17.42M持有股份
$943.61M报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 128 | +7 | 95.71M | $8.15B | +10 | −2 |
| Q1 2026 | 123 | +1 | 87.96M | $5.79B | +8 | −8 |
| Q4 2025 | 121 | -1 | 92.45M | $5.87B | +2 | −2 |
| Q3 2025 | 19 | +2 | 69.14M | $3.80B | +2 | −1 |
| Q2 2025 | 15 | -2 | 62.06M | $2.05B | — | −2 |
| Q1 2025 | 14 | +1 | 26.36M | $1.06B | +1 | — |
| Q4 2024 | 13 | -1 | 25.19M | $1.18B | — | −1 |
| Q3 2024 | 13 | +2 | 19.21M | $1.01B | +2 | — |
| Q2 2024 | 11 | — | 17.42M | $943.61M | — | — |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (被动) | 2.74M | — | $148.41M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Geode Capital Management ✦ (被动) | 2.74M | — | $148.41M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 2.36M | — | $127.78M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 2.36M | — | $127.78M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 1.68M | — | $90.92M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 1.68M | — | $90.92M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 858.97K | — | $46.54M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 858.97K | — | $46.54M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Norges Bank ✦ (被动) | 799.66K | — | $43.33M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 534.52K | — | $28.96M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Renaissance Technologies ✦ | 470.97K | — | $25.52M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Point72 Asset Management ✦ | 374.85K | — | $20.31M | 0.1% | n/c | 1 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 58.60K | — | $3.17M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 33.40K | — | $1.81M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 33.40K | — | $1.81M | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 437 持有人, 145.17M 股份, $8.22B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 18
Malik Fady Ibraham
Officer · 3.50K 股 · $265,370
Aug 10
Blum Robert I
Officer, Director · 7.50K 股 · $575,700
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 13
SC 13G/A — WELLINGTON MANAGEMENT GROUP LLP
Jul 08
SC 13G/A — FMR LLC
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据